Table 2. Drug Use Profile.
| MA users (n=28) | Cocaine users (n=9) | p-Value | |
|---|---|---|---|
| Years of drug use | 6.6±5.7 | 13.7±8.5 | 0.007 |
| Days per week (last month) | 4.3±2.4 | 1.9±1.9 | 0.08 |
| Amount per day (g) | 0.35±0.30 | 0.64±0.30 | 0.013 |
| Amount per month (g) | 1.57±1.46 | 1.38±1.90 | 0.75 |
| SDS | 4.3±2.8 | 5.3±3.7 | 0.42 |
| DAST-20 | 10.3±3.6 | 10.2±4.2 | 0.95 |
| Route of administration | 14 smoking 6 nasal 4 smoking/nasal 2 oral 2 IV | 2 smoking 7 nasal | |
| Days used (last 90 days) | 49.9±24.1 | 24.6±20.9 | 0.02 |
| Days abstinent | |||
| Before scan 1 | 2.6±2.0 (n=28) | 2.6±1.6 (n=9) | 0.91 |
| Before scan 2 | 9.9±2.3 (n=17) | 9.4±1.2 (n=8) | 0.52 |
| Drugs used recentlya | 28 MA/AM 6 MDMA/MDA 17 Cocaine/metabolites 4 Opioids 6 THC | 1 MA/AM 1 MDMA/MDA 9 Cocaine/metabolites 2 Opioids 4 THC | |
Abbreviations: AM, amphetamine; MA, methamphetamine; MDA, 3,4-methylenedioxyamphetamine; MDMA, 3,4-methylenedioxy-N-methamphetamine; THC, tetrahydrocannabinol (cannabis).
Levels of MA and MDMA were, as expected (Kalasinsky et al, 2004), higher than those of their metabolites AM and MDA, respectively, in all cases.
a
As per scalp hair data (~4–5 months before enrollment in the study, assuming a growth rate of ½ inch per month).
Bold values indicate significance at p<0.05.